Satellos resumed with a Speculative Buy at Canaccord

Canaccord analyst Tania Armstrong-Whitworth resumed coverage of Satellos (MSLE) with a Speculative Buy rating and C$19 price target The company’s lead drug SAT-3247 is being developed for the treatment of Duchenne muscular dystrophy, the analyst tells investors in a research note. The firm says SAT-3247 has demonstrated the ability to regenerate skeletal muscle lost in DMD. It forecasts peak sales of $1.5B in 2042 before estimated patent expiry, assuming 20% market uptake.